

In vivo changes in haemostasis after intravenous administration of plasma-derived factor VII and recombinant factor VII(a)

Submission date 24/06/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 12/07/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 30/10/2015	Condition category Haematological Disorders	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Factor VII is a protein produced in the liver that plays an important role in helping the blood to clot. Factor VII deficiency is a rare inherited bleeding disorder due to a diminished level of factor VII in the blood. Factor VII deficiency cannot be cured but bleeding episodes can be treated with factor VII either taken from donated blood (plasma-derived) or produced artificially (recombinant). These products are not only used to treat bleeding episodes but also to prevent bleeding. However, it is not known why this preventive treatment is successful. The aim of this study is to unravel the mode of action of both products in these patients.

Who can participate?

Patients aged 18 or older with severe factor VII deficiency.

What does the study involve?

Patients are treated with both products in a time frame of at least six weeks. Half of the patients are treated with a single injection of recombinant factor VII followed after at least six weeks with an injection of plasma-derived factor VII. The other half of the patients are treated in the reverse order.

What are the possible benefits and risks of participating?

As both products are used for the treatment of bleeding episodes in these patients the risk of adverse events is limited.

Where is the study run from?

The study will be performed at two central locations at the clinical research centers of the Radboud University of Nijmegen and in Milano.

When is the study starting and how long is it expected to run for?

May 2007 to December 2008.

Who is funding the study?

The De Erven Leeuwenhart Foundation. The products will be supplied by Novo Nordisk (recombinant factor VII) and Baxter (plasma-derived factor VII).

Who is the main contact?

Dr Waander van Heerde (Nijmegen, The Netherlands), w.vanheerde@labgk.umcn.nl

Dr Pal Andre Holme (Oslo, Norway)

Prof. Dr. Flora Peyvandi (Milan, Italy)

Contact information

Type(s)

Scientific

Contact name

Dr Waander van Heerde

Contact details

Radboud University Nijmegen Medical Center

LH 441

POBox 9101

Nijmegen

Netherlands

6500 GA

-

w.vanheerde@labgk.umcn.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

PSTOL20

Study information

Scientific Title

In vivo changes in haemostasis after intravenous administration of plasma-derived factor VII and recombinant factor VII(a): a randomised controlled cross over multicentre intervention study

Study objectives

The basis of suppletive therapy with plasma derived factor (pdF) VII or recombinant factor (rF) VIIa is not only restoration of the coagulation cascade but also presensitise platelets and effects the genetic regulation of other clotting factors

Ethics approval required

Old ethics approval format

Ethics approval(s)

Human Subjects Research Region Arnhem-Nijmegen (Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen), 30/03/2004, CMO 2003/257

Study design

Randomised controlled cross over multicentre intervention study

Primary study design

Interventional

Secondary study design

Randomised cross over trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Factor VII deficiency

Interventions

1. Ten severe factor VII patients will be treated with two factor VII containing products in a time frame of at least six weeks
2. Five patients will be treated with a single intravenous injection of recombinant activated factor VII (20 ug/kg, Novo Nordisk) followed after at least six weeks with a intravenous injection of plasma derived factor VII (25 IU/kg, Baxter)
3. The other five patients will be treated in the reverse order
4. Within 48 hours blood samples will be drawn to analyse different haemostatic parameters in their blood

Intervention Type

Biological/Vaccine

Primary outcome measure

Pharmacokinetic and pharmacodynamic analysis of recombinant activated factor VII and plasma-derived factor VII

Secondary outcome measures

No secondary outcome measures

Overall study start date

07/05/2007

Completion date

11/12/2008

Eligibility

Key inclusion criteria

1. Factor VII clotting activity of less than 5%
2. Age 18 years or older
3. Wash-out period of pdFVII or rFVII(a) of at least 3 days
4. Male or female
5. The intention to participate in a cross-over design (treated-twice)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

10

Key exclusion criteria

1. Age < 18 years
2. Known allergy to plasma proteins
3. Bleeding episode resulting in a drop in haemoglobin (Hb) levels of >1 mmol/l (64.5 g/l), trauma or surgery in the last 6 weeks
4. Fever (> 38 degrees centigrade)
5. Clinical indication of liver cirrhosis (echographic indication, enlarged spleen, enlarged liver, decreased platelet count)
6. Hepatitis C recently treated with interferon (wash-out 6 months)
7. Human immunodeficiency virus (HIV) positive
8. Pregnancy
9. Medication:
 - 9.1. Non-steroid anti-inflammatory drugs (NSAIDs)
 - 9.2. Clopidogrel
 - 9.3. Antimicrobial medication
 - 9.4. Thyroid inhibitors
 - 9.5. Serotonin-specific reuptake inhibitor (SSRIs)
 - 9.6. Hb levels < 7.5 mmol/l for women, < 8.4 mmol/l for men

Date of first enrolment

07/05/2007

Date of final enrolment

11/12/2008

Locations

Countries of recruitment

Italy

Netherlands

Norway

Study participating centre

Radboud University Nijmegen Medical Center

Nijmegen

Netherlands

6500 GA

Sponsor information

Organisation

Radboud University Nijmegen Medical Center (Netherlands)

Sponsor details

Department of Laboratory Medicine

LH 441

POBox 9101

Nijmegen

Netherlands

6500 GA

+31 (0)24 361 0800

w.vanheerde@labgk.umcn.nl

Sponsor type

University/education

Website

<http://www.ru.nl/english/>

ROR

<https://ror.org/05wg1m734>

Funder(s)

Funder type

University/education

Funder Name

Radboud University Nijmegen Medical Center (Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2013		Yes	No